Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
[Multiple sclerosis : actuality and therapeutic prospects].
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Prevention and treatment of MS: studying the effects of vitamin D.
Receptos, Inc. - Current Report: United States Securities and Exchange Commission Form 8-K
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
Helminth therapy and multiple sclerosis.
Arzerra receives approval in Japan
Transverse myelitis -- a review of the presentation, diagnosis, and initial management.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Ono to enter license agreements with Merck KGaA
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Metabolic features of the cell danger response.
A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging.
The American Academy of Neurology's Top Five Choosing Wisely recommendations.
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
Interference with RhoA-ROCK Signaling Mechanism in Autoreactive CD4(+) T Cells Enhances the Bioavailability of 1,25-Dihydroxyvitamin D(3) in Experimental Autoimmune Encephalomyelitis.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials

Pages